Phoenix Cardiac Devices announced that it received CE mark approval for its BACE device for treating functional mitral regurgitation (FMR). BACE (basal annuloplasty of the cardiac externally) is a novel modality for treating FMR and is touted as the only surgical device with long-term clinical data demonstrating significant benefit by addressing the root cause of […]
Phoenix Cardiac Devices
Phoenix Cardiac Devices initiated a clinical trial of its Bace mitral regurgitation device, designed to repair leaky heart valves without open-heart surgery.
The 60-patient study will enroll subjects in India and Europe who are suffering moderate to severe functional mitral regurgitation, according to a press release. The trial is aimed at winning CE Mark approval in the European Union.